COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020

Author:

Acosta Anna M1ORCID,Mathis Adria L12,Budnitz Daniel S13,Geller Andrew I13,Chai Shua J345,Alden Nisha B6,Meek James7,Anderson Evan J8910ORCID,Ryan Patricia11,Kim Sue12,Como-Sabetti Kathryn13,Torres Salina14,Dufort Elizabeth15,Bennett Nancy M16,Billing Laurie M17,Sutton Melissa18,Keipp Talbot H19,George Andrea20,Pham Huong1,Hall Aron J1,Fry Alicia13,Garg Shikha13,Kim Lindsay13

Affiliation:

1. COVID-NET Surveillance Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

2. All Native Synergies Company, Winnebago, Nebraska, USA

3. US Public Health Service, Rockville, Maryland, USA

4. California Emerging Infections Program, Oakland, California, USA

5. Centers for Disease Control and Prevention, Atlanta, Georgia, USA

6. Colorado Department of Public Health and Environment, Denver, Colorado, USA

7. Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA

8. Emory University School of Medicine, Atlanta, Georgia, USA

9. Georgia Emerging Infections Program, Atlanta, Georgia, USA

10. Veterans Affairs Medical Center, Atlanta, Georgia, USA

11. Maryland Department of Health, Baltimore, Maryland, USA

12. Michigan Department of Health and Human Services, Lansing, Michigan, USA

13. Minnesota Department of Health, St. Paul, Minnesota, USA

14. New Mexico Department of Health, Santa Fe, New Mexico, USA

15. New York State Department of Health, Albany, New York, USA

16. University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

17. Ohio Department of Health, Columbus, Ohio, USA

18. Oregon Health Authority, Portland, Oregon, USA

19. Vanderbilt University Medical Center, Nashville, Tennessee, USA

20. Salt Lake County Health Department, Salt Lake City, Utah, USA

Abstract

Abstract Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.

Funder

Centers of Disease Control and Prevention through an Emerging Infections Program cooperative

Council of State and Territorial Epidemiologists cooperative

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference14 articles.

1. Observational study of hydroxychloroquine in hospitalized patients with Covid-19;Geleris;N Engl J Med,2020

2. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19;Cao;N Engl J Med,2020

3. Remdesivir for the treatment of Covid-19 - preliminary report;Beigel;N Engl J Med

4. Dexamethasone in hospitalized patients with Covid-19 - preliminary report;Recovery Collaborative Group;N Engl J Med

5. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial;Li;JAMA

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3